Cantor Fitzgerald calls attention to Alnylam’s Amvuttra’s 30% royalty burden
Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...
BioSpace5d
Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ...
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
FDA approves new drug to treat protein buildup in the heart
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Fierce Pharma5d
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...
BioPharma Dive5d
Alnylam drug gets long-awaited FDA approval in deadly heart disease
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
EconoTimes4d
Alnylam’s Amvuttra Wins FDA Approval, Challenges Pfizer in $11B Heart Drug Market
The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals drug Amvuttra to treat transthyretin amyloid ...
Alnylam's Amvuttra Gets Approval for Expanded Indication From FDA
Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.